首页>投融资
Gynesonics
收并购
Gynesonics is a developer of transcervical, uterus-preserving, incision-free technologies for diagnostic and therapeutic applications (avoiding invasive surgical techniques of hysterectomy or myomectomy for symptomatic uterine fibroids). Products include the Sonata system which combines intrauterine ultrasound guidance with targeted radiofrequency ablation.In April 2023, the company closed a financing round of $25M
基本信息
-
公司全称Gynesonics Inc
-
类型子宫肌瘤微创解决方案研发商
-
产业领域医疗器械、治疗设备
-
公司人数15~50人
-
地址604 Fifth Avenue,Suite D REDWOOD CITY CALIFORNIA 94063; US; Telephone: +16502163860; Fax: +16502991566;
-
联系电话1(650)216-3860
-
邮箱info@gynesonics.com
-
成立时间2005-01-01
投融资
-
2025-01-06收并购3.5亿美元Hologic
-
2023-11-01未透露4250万美元Endeavour VisionMVMAmzak Health InvestorsBain CapitalRunway Growth CapitalKaiser Permanente Ventures
-
2023-04-11未透露2500万美元未透露
-
2021-01-13债权融资5000万美元Runway Growth Capital
-
2019-01-03股权融资7500万美元InterWest PartnersHBM PartnersHercules Technology Growth CapitalBain CapitalCorrelation Ventures
-
2015-10-17股权融资未透露Advanced Technology VenturesInterWest PartnersHBM PartnersHercules Technology Growth CapitalNovit VenturesCorrelation Ventures
-
2015-07-22未透露未透露Advanced Technology VenturesHercules CapitalInterWest PartnersHBM PartnersEndeavour VisionCorrelation Ventures
- 加载更多
相关投融资企业
C轮
Francis Medical is a dynamic medical device company committed to developing urological cancer treatments that are tough on cancer yet gentle on patients.In September 2020, Coloplast announced that it has completed a USD 4m (DKK 25m) equity investment in Francis Medical
收并购
Gynesonics is a developer of transcervical, uterus-preserving, incision-free technologies for diagnostic and therapeutic applications (avoiding invasive surgical techniques of hysterectomy or myomectomy for symptomatic uterine fibroids). Products include the Sonata system which combines intrauterine ultrasound guidance with targeted radiofrequency ablation.In April 2023, the company closed a financing round of $25M
未公开
BetaGlue Therapeutics是一家临床分期肿瘤公司,该公司开发了一种先进的放疗平台,能够对不可切除的实体瘤和手术切缘进行局部靶向治疗,称为YntraDose。